Results 161 to 170 of about 8,307,299 (283)
Molecular Oncology, EarlyView.Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley +1 more source
From Plant Material to Environmentally Friendly Plant Growth Stimulators: Betaine-Based Ionic Liquids. [PDF]
ACS Sustain Chem EngOlejniczak A +6 more
europepmc +1 more source
THE OCCURRENCE OF ERGOTHIONEINE IN PLANT MATERIAL
Journal of Biological Chemistry, 1956 D B, MELVILLE, S, EICH
openaire +2 more sources
CEACAM1 participation in breast cancer progression
Molecular Oncology, EarlyView.In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin +3 more
wiley +1 more source
Public health review Trojan nuclear power plant
, 1970 This archived document is maintained by the Oregon State Library as part of the Oregon Documents Depository Program. It is for informational purposes and may not be suitable for legal purposes.Title from cover.Includes individual recommendation ...
core
Three year retained orbital plant material. [PDF]
Am J Ophthalmol Case RepRaikar DG, Winkler KP.
europepmc +1 more source
PlantCrystals-Nanosized Plant Material for Improved Bioefficacy of Medical Plants. [PDF]
Materials (Basel), 2020 Abraham AM +3 more
europepmc +1 more source
Restoration of species-rich grasslands by transfer of local plant material and its impact on species diversity and genetic variation-Findings of a practical restoration project in southeastern Germany. [PDF]
Ecol Evol, 2021 Kaulfuß F, Reisch C.
europepmc +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Molecular Oncology, EarlyView.Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source